ライフサイエンスコーパス: stroke

1 (1505 with no prior myocardial infarction or stroke).

2 lasty, coronary artery bypass graft surgery, stroke).

3 c injury, and presumed perinatal hemorrhagic stroke.

4 nts had either device thrombosis or ischemic stroke.

5 to mediate this skill due to training after stroke.

6 n these complex patients with acute ischemic stroke.

7 similar in magnitude to CHD and greater than stroke.

8 ar death, myocardial infarction, or ischemic stroke.

9 ective wild-type controls to photothrombotic stroke.

10 DP, preterm delivery, and stillbirth for any stroke.

11 anagement of cerebral emergencies other than stroke.

12 uations in people with chronic aphasia after stroke.

13 ogical hypothermia as a treatment option for stroke.

14 ency, index admission for heart failure, and stroke.

15 ic kidney disease, and large-artery ischemic stroke.

16 increased risk for myocardial infarction and stroke.

17 r (13 studies) and 5 years (8 studies) after stroke.

18 rombectomy improves outcomes at 90 days post stroke.

19 rease at 14d and a second decrease 28d after stroke.

20 ow-up Study since 2004, without a history of stroke.

21 ment depends on the specific pathogenesis of stroke.

22 the first nonfatal stroke or death owing to stroke.

23 Hg, 0.87; 95% CI, 0.78-0.98), but not prior stroke.

24 reased risk of stroke overall or hemorrhagic stroke.

25 as positively associated with early ischemic stroke.

26 covery within the first six months after the stroke.

27 d opportunity to prevent recurrent disabling stroke.

28 n 140 mm Hg to reduce the risk for recurrent stroke.

29 ogy of cardiovascular diseases, particularly stroke.

30 ptomatic carotid disease and recent ischemic stroke.

31 valence of associated risk factors for acute stroke.

32 mice were also tracked after parturition and stroke.

33 intermediates in mouse brain during ischemic stroke.

34 is also limited to the first few weeks after stroke.

35 iated with a 5-fold increase in the risk for stroke.

36 ith LV thrombus displayed a very low rate of stroke (0%), peripheral embolism (0%), and severe hemorr

37 The annual increase in disability before stroke (0.06 points per year; 95% CI, 0.002 to 0.12; P =

38 02 to 0.12; P = .04) more than tripled after stroke (0.15 additional points per year; 95% CI, 0.004 t

39 y near the time of the event was greater for stroke (0.88 points on the disability scale; 95% CI, 0.5

40 disease (30 more cases [95% CI, 16 to 48]), stroke (11 more cases [95% CI, 2 to 23]), venous thrombo

41 vascular complications (6.11% to 4.20%), and stroke (2.03% to 1.66%).

42 t no statistically significant difference in stroke (3 NOACs pooled).

43 f the 597 disabling/fatal incident ischaemic strokes, 369 occurred at age >/=80 years, of which 124 (

44 disease (21 more cases [95% CI, 10 to 34]), stroke (9 more cases [95% CI, 2 to 19]), urinary inconti

45 a 2.49-fold increased odds of cardioembolic stroke (95% confidence interval, 1.39-4.58; P=2.7x10(-3)

46 Intracerebral hemorrhage and ischemic stroke admissions were identified from the Nationwide In

47 H lesion pattern among patients with embolic stroke aetiology.

48 otic refilling of TCA cycle intermediates in stroke-affected brain.

49 r RAMT(+) groups (30 min daily RAMT over the stroke-affected gastrocnemius) and were followed up to p

50 n ovale (PFO) in the prevention of recurrent stroke after cryptogenic stroke is uncertain.

51 f intravenous thrombolysis in acute ischemic stroke (AIS).

52 n underlying mechanism linking DHI's role in stroke and CAD treatment was inflammatory response in th

53 Here we show that in patients with ischemic stroke and in mice subjected to middle cerebral artery o

54 DL) and non-HDL cholesterol, and extended to stroke and myocardial infarction.

55 brain contributes to neuronal injury during stroke and other cerebrovascular diseases.

56 Stroke and potentially life-threatening complications, s

57 utcomes of inpatient admissions for ischemic strokes and major bleeding were compared across the 3 dr

58 nts for an increasing proportion of ischemic strokes and might multiply several-fold during the next

59 to the leading head (deemed to be the power stroke) and diffusion of the trailing head (TH) that con

60 ocardial infarction, 11 (0.9%) with ischemic stroke, and 1 (0.1%) with deep venous thrombosis; 28 pat

61 by medical claims was 4.3% for MI, 0.9% for stroke, and 5.0% for bleeding.

62 racranial hemorrhage, 68.2% in patients with stroke, and 50% in patients with seizures.

63 a composite of mortality, clinical ischemic stroke, and acute kidney injury within 30 days after sur

64 diseases including multiple sclerosis (MS), stroke, and Alzheimer's disease.

65 sex, hypertension, type 2 diabetes, previous stroke, and anticoagulation, incident AF patients with v

66 ong-term mortality and rates of reoperation, stroke, and bleeding between inverse-probability-weighte

67 150 mm Hg to reduce the risk for mortality, stroke, and cardiac events.

68 and nonfatal myocardial infarction, ischemic stroke, and cardiovascular death.

69 th conventional cardiovascular risk factors, stroke, and chronic kidney disease.

70 ratios for incident coronary heart disease, stroke, and CVD associated with a 1-SD decrease in mtDNA

71 ing nonfatal myocardial infarction, nonfatal stroke, and CVD mortality.

72 Death, stroke, and days alive and out of the hospital to 1 year

73 lization for myocardial infarction, ischemic stroke, and heart failure.

74 injury was defined as brain death, seizures, stroke, and intracranial hemorrhage occurring during ext

75 generative diseases, after trauma, and after stroke, and is characterized by increased reflexes leadi

76 reversal of warfarin effects in haemorrhagic stroke, and management of cerebral emergencies other tha

77 and gestational hypertension for hemorrhagic stroke, and oophorectomy, HDP, preterm delivery, and sti

78 RV], microalbuminuria, leg ulcers, priapism, stroke, and osteonecrosis) by clinical examination, labo

79 4 Western data, rates of procedural success, stroke, and paraplegia appeared similar, while those for

80 -related conditions including heart disease, stroke, and type 2 diabetes are leading causes of preven

81 63.3%) versus 49.7% medical mimics and 45.5% stroke, and younger (mean age (SD)) 49.1 (18.8) than med

82 04), poor cognitive outcome (P = 0.03), post-stroke anxiety (P = 0.04) and post-stroke depression (P

83 rates of cardiovascular (CV) death, MI, and stroke as well as TIMI major bleeding were analyzed at y

84 ed endpoint was cardiovascular death, MI, or stroke at 1 year.

85 who were free of cancer, heart disease, and stroke at baseline.

86 Strokes at 30 days were 9.1% in control subjects and 5.6

87 ny of these 16 genes are predictive for post-stroke blood brain barrier (BBB) disruption.

88 ke has not only identified those at risk for stroke but also identified ways to target at-risk popula

89 ity of disordered coagulation at the time of stroke but suggests testing in childhood is not indicate

90 g approach, since cortical dysfunction after stroke can arise from cortical damage or from white matt

91 However, there was no difference in nonfatal stroke, cardiovascular disease mortality, or all-cause m

92 ences in hemorrhagic stroke, disabling/fatal stroke, cardiovascular/unexplained death, all-cause deat

93 he use of telemedicine in cardiovascular and stroke care and to provide consensus policy suggestions.

94 c stroke in a separate study of 509 ischemic stroke cases (202 cardioembolic [40%]) and 3028 referent

95 ) than medical mimic (63.5 years (16.7)) and stroke cases (71 years (15.5)).

96 cal outcomes in patients with acute ischemic stroke caused by intracranial proximal occlusion.

97 hospital triage to the closest comprehensive stroke center (CSC) may improve the delivery of care for

98 nts with ELVO who first present to a primary stroke center (PSC).

99 elevated in stroke patients relative to non-stroke control groups, and negatively associated with po

100 plasticity in the spinal cord during chronic stroke could improve recovery from persistent sensorimot

101 d cumulative CVD (coronary heart disease and stroke) deaths prevented or postponed and life-years gai

102 orsening heart failure, atrial fibrillation, stroke, deep venous thrombosis, cardiovascular death, an

103 r death owing to coronary heart disease, and stroke, defined as the first nonfatal stroke or death ow

104 03), post-stroke anxiety (P = 0.04) and post-stroke depression (P = 0.02).

105 eatine kinase, and the rates of bleeding and stroke did not differ significantly between the two grou

106 However, differences in hemorrhagic stroke, disabling/fatal stroke, cardiovascular/unexplain

107 y endarterectomy (CEA) for the prevention of stroke due to carotid artery stenosis.

108 disruption of areas seemingly spared by the stroke due to loss of white matter connectivity and netw

109 to serious maternal complications, including stroke, eclampsia, and organ failure.

110 vents, including the first and all recurrent strokes, ezetimibe/simvastatin reduced stroke of any eti

111 prove the accuracy of predictability in post-stroke functional impairment.

112 ionally dependent or dead 3 months postacute stroke; functional recovery rates varied considerably am

113 The use of neuroprotective agents in stroke has been a notable failure of translation from me

114 Although ischemic stroke has been found to be associated with many biologi

115 in mortality from coronary heart disease and stroke has been the success story of the century's past

116 t research into risk factors and genetics of stroke has not only identified those at risk for stroke

117 RTICLE: About 20% of patients with ischaemic stroke have a preceding transient ischaemic attack, whic

118 the correct diagnosis is important, as these strokes have a high chance of recurrence, can be life th

119 ology care was associated with reductions in stroke (hazard ratio [HR]: 0.91; 95% confidence interval

120 se with high risk of cardiovascular disease, stroke, heart failure, and atrial fibrillation.

121 Incident CVD included CHD, stroke, heart failure, and peripheral arterial disease.

122 tal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitali

123 332 ischemic stroke patients from 1494 GWTG-Stroke hospitals were included; mean age was 80 years, 5

124 83; 95% CI, 0.70-0.98; P=0.029) and ischemic stroke (HR, 0.76; 95% CI, 0.63-0.91; P=0.003).

125 (HR, 2.4; 95% CI, 1.7-3.5) than for ischemic stroke (HR, 1.3; 95% CI, 1.2-1.5).

126 lder, smokers, have a history of hemorrhagic stroke, hypothyroidism, and dementia, and less likely to

127 the three ATPase-dependent 120 degrees power strokes imposed by the relative positions of the central

128 are GA with CS for treatment of endovascular stroke in 73 and 77 patients, respectively.

129 between AF genetic risk scores and ischemic stroke in a separate study of 509 ischemic stroke cases

130 Acute ischaemic stroke in brain areas contributing to male sexual functi

131 cohort study of patients admitted with acute stroke in England and Wales.

132 lure (HF), coronary heart disease (CHD), and stroke in participants with vs without CKD.

133 1a reduces neuronal death following ischemic stroke in rodents.

134 tid atherosclerosis, as well as with risk of stroke in this population.

135 as positively associated with early ischemic stroke in women (HR, 1.10; 95% CI, 1.01-1.20) and in men

136 the region of interest and region damaged by stroke, in particular within the parietal association an

137 Increasing trends in stroke incidence and hospitalizations have been noted am

138 A high-fat diet accelerated stroke incidence.

139 small dose of Hi1a (2 ng/kg) up to 8 h after stroke induction by occlusion of the middle cerebral art

140 ld-type mice with C3a beginning 7 days after stroke induction robustly increased synaptic density (P

141 elevated in activated microglia in models of stroke, infection and traumatic brain injury, though the

142 Understanding thrombophilia in perinatal stroke informs pathogenesis models and clinical manageme

143 Consecutive patients with acute ischemic stroke initially admitted to a non-thrombectomy-capable

144 ted hypothermia by DHC on long-term ischemic stroke injury and functional outcome.

145 , and Parkinson's diseases), carcinogenesis, stroke, intracerebral hemorrhage, traumatic brain injury

146 Ischemic stroke, intracranial hemorrhage, extracranial bleeding,

147 Stroke is a heterogeneous syndrome, and determining risk

148 y cause rare, hereditary disorders for which stroke is a primary manifestation.

149 pathways, the genetic mechanism of ischemic stroke is still unclear.

150 ention of recurrent stroke after cryptogenic stroke is uncertain.

151 x relationship between migraine and ischemic stroke (IS).

152 is common in the first few days after acute stroke, is frequently intermittent, and is often undetec

153 The diagnosis of stroke, its underlying aetiology, theranostic strategies

154 Large artery atherosclerotic stroke (LAS) shows substantial heritability not explaine

155 aged 70 years or younger with aphasia after stroke lasting for 6 months or more were recruited from

156 e and having AF first diagnosed >7 days post-stroke (late AF) was highly associated with recurrent st

157 reasing stroke risk include HDP for ischemic stroke, late menopause and gestational hypertension for

158 suggesting that the closer a region is to a stroke lesion, the more it would be affected during func

159 hondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome, however, the comm

160 rial encephalomyopathy, lactic acidosis, and stroke-like episodes.

161 1.9%; ES3, 1.8%; P=0.87), rate of disabling stroke (Lotus, 1.5%; ES3, 2.1%; P=0.62), or major vascul

162 groups, and negatively associated with post-stroke lymphocyte counts.

163 =1.21; P=0.021) but a similar risk of death, stroke, major bleeding, and all-cause hospitalization.

164 anslation into clinical bedside practice for stroke management.

165 While stroke mortality rates have decreased substantially in t

166 The pooled relative risk of stroke mortality was 1.57 (95% CI, 1.04-2.39) after GH v

167 g cause-specific (heart disease, cancer, and stroke) mortality rates.

168 e composite outcome of periprocedural death, stroke, myocardial infarction (MI), or nonperiprocedural

169 in humans are associated with hypertension, stroke, myocardial infarction, and vascular diseases.

170 t difference in mortality and combined death/stroke/myocardial infarction were observed.

171 transferred from 1 of 30 RHs in our regional stroke network and presenting at our TCSC from January 1

172 in several neuronal disorders, like ischemic stroke, neuronal inflammation, and pathological pain.

173 Hypothermia shows promise for stroke neuroprotection, but current cooling strategies c

174 We show that the power stroke occurs in two major steps.

175 F variants were not associated with incident stroke (odds ratio, 0.84; 95% CI, 0.48-1.47 in blacks an

176 rrent strokes, ezetimibe/simvastatin reduced stroke of any etiology (HR, 0.83; 95% CI, 0.70-0.98; P=0

177 iomyopathy may explain many cases of embolic stroke of undetermined source, and oral anticoagulant dr

178 were younger and had a shorter delay between stroke onset and randomisation but they had similar pre-

179 The prediction of infarction volume after stroke onset depends on the shape of the growth dynamics

180 e, and stroke, defined as the first nonfatal stroke or death owing to stroke.

181 resistance, those at higher risk for future stroke or myocardial infarction (MI) derive more benefit

182 t trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) within 48 h o

183 a subgroup analysis of patients in the Acute Stroke or Transient Ischaemic Attack Treated with Aspiri

184 ine whether, among patients with an ischemic stroke or transient ischemic attack and insulin resistan

185 of diplopia-related ED visits resulted in a stroke or transient ischemic attack diagnosis.

186 lts aged 60 years or older with a history of stroke or transient ischemic attack to achieve a target

187 ncluding arterial thromboembolic events, MI, stroke or transient ischemic attack, vascular deaths, an

188 During follow-up, 62 strokes or TIAs, 42 myocardial infarctions, 156 HF event

189 duce the composite of myocardial infarction, stroke, or cardiovascular death in patients with establi

190 unstable angina, arterial revascularization, stroke, or cardiovascular death) were compared to age- a

191 and the risk of CVD (myocardial infarction, stroke, or cardiovascular death); 2) a MedDiet intervent

192 nt (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death.

193 efit was observed for myocardial infarction, stroke, or hospital admission for heart failure.

194 e of all-cause death, myocardial infarction, stroke, or repeat revascularization at long-term follow-

195 utcomes (i.e., coronary heart disease [CHD], stroke, or the combination of both).

196 carcinoma transcript 1 (Malat1), in ischemic stroke outcome.

197 se was not associated with increased risk of stroke overall or hemorrhagic stroke.

198 Could this 'stroke paradox' be a result of the increased haematocrit

199 (2006-2013) on acute complicated type B AD, stroke, paraplegia, in-hospital mortality and follow-up

200 MATERIAL/Forty-five stroke patients and 45 age- and sex-matched controls wer

201 , novel medical options for the treatment of stroke patients are also under investigation, such as pr

202 A total of 535 332 ischemic stroke patients from 1494 GWTG-Stroke hospitals were inc

203 ty and soluble CD163 levels were elevated in stroke patients relative to non-stroke control groups, a

204 Hemiplegic stroke patients should undergo ultrasonography of the he

205 One third of acute ischemic stroke patients were functionally dependent or dead 3 mo

206 A total of 16 901 ischemic stroke patients were treated with intravenous tPA within

207 We assessed functional outcome in ischaemic stroke patients with large vessel anterior circulation o

208 Although stroke patients without tPA treatment gradually repopula

209 l for refining rehabilitation strategies for stroke patients.

210 The implementation of Target: Stroke Phase I, the first stage of the American Heart As

211 latory T cells within the first 7 days after stroke, post-ischaemic tPA treatment led to sustained su

212 U.S. Food and Drug Administration (FDA) as a stroke prevention alternative to warfarin for patients w

213 lactic exclusion of the LAA is warranted for stroke prevention during non-atrial fibrillation-related

214 be a reasonable alternative to warfarin for stroke prevention in patients on dialysis.

215 g and concomitant cardiovascular conditions, stroke prevention therapy, rate control, and rhythm cont

216 ified ways to target at-risk populations for stroke prevention.

217 indication may decrease the effectiveness of stroke prevention.

218 ergic receptor antagonism after experimental stroke prevents loss of splenic MZ B cells, preserves Ig

219 -day mortality, in-hospital and 30-day death/stroke, procedural success, intensive care unit and hosp

220 The Alberta Perinatal Stroke Project, a provincial registry, ascertained NHS c

221 ns to determine the variations of AF-induced stroke propensity over various image-based patient-depen

222 % decrease in DTN time, 95% CI 3%-20%), STAT stroke protocol (11% decrease in DTN time, 95% CI 1%-20%

223 ess than one-third that of the mean European stroke rate (P<0.0001).

224 The mean North American stroke rate was less than one-third that of the mean Eur

225 nt with AF, the threshold of annual ischemic stroke rate where the benefit of anticoagulation outweig

226 the primary endpoint, 30-day post-operative stroke rate, were included in a Bayesian network meta-an

227 .5 days, P<0.001), and combined 30-day death/stroke rates (4.8% versus 6.4%, P<0.001).

228 The majority of cohorts did not observe stroke rates that would indicate a clear expected net cl

229 The acceleration data showed that stroke rates, including tail beat and whole-body movemen

230 an Heart Association Get With The Guidelines-Stroke Registry, we examined the outcomes of use of thro

231 current stimulation (tDCS) has been used in stroke rehabilitation, though their combinatory effect i

232 rom myocardial infarction, heart failure, or stroke, respectively, than members of the general popula

233 s of death, including cancer, heart disease, stroke, respiratory disease, and infection.

234 oral anticoagulant drugs may prove to reduce stroke risk from atrial cardiomyopathy given its paralle

235 Female-specific characteristics increasing stroke risk include HDP for ischemic stroke, late menopa

236 Stroke risk pathogenesis may include factors that are pr

237 PCSK9 LOF variants were not associated with stroke risk.

238 tral adiposity may have a stronger effect on stroke risk.

239 life experiences such as pregnancy increase stroke risk.

240 nfarction (RR, 0.47; 95% CI, 0.20-1.11), and stroke (RR, 1.26; 95% CI, 0.70-2.26) at 30 days.

241 lation (median National Institutes of Health Stroke Scale 12, 13, and 9, respectively).

242 re included (mean age = 66 years, median NIH Stroke Scale [NIHSS] = 16, median time from symptom onse

243 95% CI 6%-31%; National Institutes of Health Stroke Scale score >8: 27% decrease in DTN time, 95% CI

244 roke severity (National Institutes of Health Stroke Scale score 6-8: 19% decrease in DTN time, 95% CI

245 1% decrease in DTN time, 95% CI 1%-20%), and stroke severity (National Institutes of Health Stroke Sc

246 luded age, prestroke functional limitations, stroke severity, and history of atrial fibrillation.

247 y in women is mostly because of age but also stroke severity, atrial fibrillation, and prestroke func

248 Sixteen of 64 (25%) had a stroke soon after starting antiretroviral therapy (ART),

249 is of several neurological disorders such as stroke, spinal cord injury, multiple sclerosis, amyotrop

250 e Enhanced Control of Hypertension and Acute Stroke Study (ENCHANTED) and the clinical predictors of

251 ons for Geographic and Racial Differences in Stroke study (REGARDS) by sex.

252 ders, 25 (55.6%) unaffected shoulders of the stroke subjects, and 39 (43.3%) control shoulders.

253 y (MT) is beneficial for patients with acute stroke suffering a large-vessel occlusion, although trea

254 f Caregiving), were used to identify elderly stroke survivors and their caregivers.

255 pole is not commonly completely lesioned in stroke survivors and this heterogeneity may have prevent

256 a-analysis shows that about one out of eight stroke survivors has suicidal ideation.

257 Black stroke survivors received an average of approximately 11

258 stroke survivors were more likely than white stroke survivors to have a caregiver (62.5% versus 49.7%

259 Black stroke survivors were more likely than white stroke surv

260 Many stroke survivors with aphasia in the acute period experi

261 proximately 11 more hours of care than white stroke survivors without substantial differences in unme

262 ccurrence of SCAF in those with a history of stroke, systemic embolism, or transient ischemic attack

263 We compared the rates of stroke/systemic embolism at 1 year according to diabetes

264 nticoagulation therapy for the prevention of stroke/systemic embolism in patients with atrial fibrill

265 rincipal effectiveness end point of ischemic stroke/systemic embolism, no significant differences of

266 iated with a lower risk of first-time MI and stroke than ASA monotherapy.

267 ily) has been associated with lower rates of stroke than warfarin in trials of atrial fibrillation, b

268 rbid conditions, and experienced more severe strokes than did those who were not on anticoagulation (

269 atients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stroke was lower

270 al calcium pathways as potential targets for stroke therapy.

271 r centers from abnormal cortical input after stroke, thus allowing for compensatory and independent a

272 ate AF) was highly associated with recurrent stroke/TIA (hazard ratio, 2.0; 95% confidence interval,

273 t methodologies and clinical applications in stroke to help build a consensus for what should be incl

274 l myocardial infarction [MI], heart failure, stroke, transient ischemic attack, peripheral arterial c

275 cohort of patients with anterior circulation stroke treated with MT and achieving a final mTICI score

276 mon use of thrombolytic drugs, especially in stroke treatment, there are many conflicting studies on

277 -7, -1; P=0.03) gradients, without affecting stroke volume 3 mL/m(2) (-2, 8; P=0.16).

278 ), pulse pressure variation (one trial), and stroke volume change with passive leg raise/fluid challe

279 ardiac electromechanics, cardiac output, and stroke volume in the perioperative setting.

280 ts with reduced aortic valve area and normal stroke volume index undergoing AVR underwent echocardiog

281 used to assess fluid responsiveness included stroke volume variation (nine trials), pulse pressure va

282 olute change in pulse pressure variation and stroke volume variation after increasing tidal volume fr

283 variable, pulse distension (a surrogate for stroke volume) was improved in the neurokinin-1 receptor

284 erectile dysfunction scores before and after stroke was correlated with the lesion site using t-test

285 enic stroke, the risk of subsequent ischemic stroke was lower among those assigned to PFO closure com

286 ction (MI), or nonperiprocedural ipsilateral stroke was not significantly different between therapies

287 this brain region is often spared in aphasic stroke, we propose that it is a sensible target for futu

288 n men, the pooled relative risks of ischemic stroke were 1.19 (95% CI, 1.05-1.34) after androgen depr

289 yocardial infarction, revascularization, and stroke were also analyzed.

290 The underlying chronic strokes were variably sized, predominantly affected whit

291 iovascular death, myocardial infarction, and stroke when compared with patients enrolled based on the

292 w myocardial infarction, angina pectoris, or stroke, which developed between baseline and follow-up.

293 autologous, multifunctional cell therapy for stroke, which is the primary cause of long term disabili

294 rombolytic therapy in patients with ischemic stroke who received anticoagulation with NOACs versus th

295 ticoagulants among patients at high risk for stroke with a previously placed implantable CIED, but wi

296 , patients with acute middle cerebral artery stroke with absence of cortical vein opacification in th

297 d point was all-cause mortality or disabling stroke within 12 months.

298 plan-Meier estimate of the incidence of TIA /stroke within 3 months after onset was 6% (95% CI: 2%, 1

299 Chondroitinase ABC injection during chronic stroke without additional training resulted in moderate

300 nd improved myocardial efficiency defined as stroke work/myocardial oxygen consumption (r=0.63-0.65;